loading page

Remdesivir for Covid-19 pneumonia in patients with severe chronic kidney disease: Case series and review of the literature
  • +5
  • Ahmad Al Bishawi,
  • Hamad Abdel Hadi,
  • Eman Elmekaty,
  • Musaed Al Samawi,
  • Arun Nair,
  • mohamed aboukamar,
  • Muna AlMaslamani,
  • Alaaeldin Abdelmajid
Ahmad Al Bishawi
Hamad Medical Corporation
Author Profile
Hamad Abdel Hadi
Hamad Medical Corporation
Author Profile
Eman Elmekaty
Hamad Medical Corporation
Author Profile
Musaed Al Samawi
Hamad Medical Corporation
Author Profile
Arun Nair
Hamad Medical Corporation
Author Profile
mohamed aboukamar
Hamad Medical Corporation
Author Profile
Muna AlMaslamani
Hamad Medical Corp
Author Profile
Alaaeldin Abdelmajid
Hamad General Hospital
Author Profile

Abstract

Remdesivir was the first antiviral agent to receive FDA authorization for severe COVID-19 management, which restricts its use with severe renal impairment due to concerns that active metabolites might accumulate, causing renal toxicities. With limited treatment options, available evidence on such patient groups is important to assess for future safety.
26 Dec 2021Submitted to Clinical Case Reports
28 Dec 2021Submission Checks Completed
28 Dec 2021Assigned to Editor
03 Jan 2022Reviewer(s) Assigned
15 Jan 2022Review(s) Completed, Editorial Evaluation Pending
23 Jan 2022Editorial Decision: Revise Minor
26 Jan 20221st Revision Received
27 Jan 2022Submission Checks Completed
27 Jan 2022Assigned to Editor
27 Jan 2022Review(s) Completed, Editorial Evaluation Pending
01 Feb 2022Editorial Decision: Accept
Feb 2022Published in Clinical Case Reports volume 10 issue 2. 10.1002/ccr3.5467